Unicycive Therapeutics, Inc.
UNCY
$0.64
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 91.01% | 24.94% | 23.26% | 29.51% | 40.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.70% | 5.27% | 71.24% | 88.74% | 18.55% |
| Operating Income | -46.70% | -5.27% | -71.24% | -119.06% | -18.55% |
| Income Before Tax | -176.03% | 5.47% | 356.77% | -43.83% | -46.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -176.03% | 5.47% | 356.77% | -43.83% | -46.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -176.03% | 5.47% | 356.77% | -43.83% | -46.36% |
| EBIT | -46.70% | -5.27% | -71.24% | -119.06% | -18.55% |
| EBITDA | -46.66% | -5.21% | -71.32% | -118.95% | -18.54% |
| EPS Basic | 8.99% | 65.85% | 127.55% | 54.91% | 36.70% |
| Normalized Basic EPS | 8.94% | 65.30% | 203.17% | 37.19% | 36.71% |
| EPS Diluted | 8.99% | 65.85% | 49.78% | 54.91% | 36.70% |
| Normalized Diluted EPS | 8.94% | 65.30% | 141.59% | 37.19% | 36.71% |
| Average Basic Shares Outstanding | 203.30% | 172.56% | 148.87% | 128.99% | 131.19% |
| Average Diluted Shares Outstanding | 203.30% | 172.56% | 517.36% | 128.99% | 131.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |